Novo Nordisk’s Ozempic and Wegovy, long in shortage, are now listed as available by FDA
Semaglutide, the scientific name for Novo’s GLP-1 diabetes drug Ozempic and obesity drug Wegovy, has been on the shortage list for over two years, with different doses being listed in shortage at various times.
As if there weren't enough reasons to buy shares of the cardiometabolic drug juggernauts Eli Lilly (LLY 0.74%) and Novo Nordisk (NVO -0.28%), there's now one more big reason to ex ...
Eli Lilly (LLY) stock drops hurting its rival Novo Nordisk (NVO) after the U.S. drugmaker missed forecasts with Q3 financials and weight loss drugs. Read more here.
A former regional account manager working for Novo Nordisk Inc. is suing the healthcare company, alleging it failed to ...
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...
Novo Nordisk faces competition from Eli Lilly in new therapeutic areas. Read why I rate NONOF stock as a hold.
Novo Nordisk A/S has fallen behind Eli Lilly & Co. this year in the race to be the big stock market winner from obesity drugs ...
Roche recently joined naysayers who argue the deal threatens competition in the burgeoning weight loss and diabetes drug ...
Hims & Hers (HIMS) stock fell 14% following news that Novo Nordisk’s (NVO) weight-loss drug Wegovy is no longer ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback